<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831609</url>
  </required_header>
  <id_info>
    <org_study_id>2011-07-089-013</org_study_id>
    <nct_id>NCT01831609</nct_id>
  </id_info>
  <brief_title>Biomarker Analysis of Gastrointestinal, Genitourinary, Sarcoma, Rare Cancer</brief_title>
  <official_title>Biomarker Analysis of Gastrointestinal, Genitourinary, Sarcoma, Rare Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary
      cultures from metastatic cancer patients. The specimens will be analyzed using
      DNA/RNA/proteomic approaches.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Biomarker analyses to predict treatment response in metastatic cancer</measure>
    <time_frame>3 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Sarcoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pleural fluid, ascites, fine needle aspirations, other body fluids (i.e. CSFs)prospectively.
      Primary cultures, Xenografts.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare
        cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare
             cancer

          2. Written informed consent

          3. body fluid derived from cancer, available for drainage and collection

        Exclusion Criteria:

          -  patients who do not give informed consent form for research use of
             biomaterials/biospecimens
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeeyun Lee, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeeyun Lee, MD</last_name>
    <phone>822-3410-3459</phone>
    <email>jyun.lee@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyejin Jang, RN</last_name>
      <phone>822-3410-6859</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal</keyword>
  <keyword>Genitourinary</keyword>
  <keyword>Rare Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
